## Pavel MÃ;jek

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7155491/publications.pdf

Version: 2024-02-01

840776 752698 33 451 11 20 citations h-index g-index papers 33 33 33 745 docs citations times ranked citing authors all docs

#	Article	IF	Citations
1	Complete Identification of Proteins Responsible for Human Blood Plasma Fouling on Poly(ethylene) Tj ${\sf ETQq1\ 1}$	0.78431	4 rgBT /Overloci
2	Proteome changes in platelets activated by arachidonic acid, collagen, and thrombin. Proteome Science, 2010, 8, 56.	1.7	44
3	Acquired Dysfibrinogenemia Secondary to Multiple Myeloma. Acta Haematologica, 2008, 120, 75-81.	1.4	34
4	Antioxidants change platelet responses to various stimulating events. Free Radical Biology and Medicine, 2009, 47, 1707-1714.	2.9	33
5	Plasma proteome changes in cardiovascular disease patients: novel isoforms of apolipoprotein A1. Journal of Translational Medicine, 2011, 9, 84.	4.4	30
6	Plasma proteome changes associated with refractory cytopenia with multilineage dysplasia. Proteome Science, 2011, 9, 64.	1.7	18
7	Surface plasmon resonance: advances of label-free approaches in the analysis of biological samples. Bioanalysis, 2014, 6, 3325-3336.	1.5	17
8	Proteome Changes in the Plasma of Myelodysplastic Syndrome Patients with Refractory Anemia with Excess Blasts Subtype 2. Disease Markers, 2014, 2014, 1-8.	1.3	16
9	Impact of posttranslational modifications on atomistic structure of fibrinogen. PLoS ONE, 2020, 15, e0227543.	2.5	16
10	Plasma proteome changes associated with refractory anemia and refractory anemia with ringed sideroblasts in patients with myelodysplastic syndrome. Proteome Science, 2013, 11, 14.	1.7	15
11	Plasma protein alterations in the refractory anemia with excess blasts subtype 1 subgroup of myelodysplastic syndrome. Proteome Science, 2012, 10, 31.	1.7	12
12	Enhanced plasma protein carbonylation in patients with myelodysplastic syndromes. Free Radical Biology and Medicine, 2017, 108, 1-7.	2.9	12
13	Endothelialization of an ePTFE vessel prosthesis modified with an antithrombogenic fibrin/heparin coating enriched with bound growth factors. RSC Advances, 2021, 11, 5903-5913.	<b>3.</b> 6	11
14	Improved Coomassie Blue Dye-Based Fast Staining Protocol for Proteins Separated by SDS-PAGE. PLoS ONE, 2013, 8, e81696.	2.5	8
15	A novel natural mutation AαPhe98Ile in the fibrinogen coiled-coil affects fibrinogen function. Thrombosis and Haemostasis, 2014, 111, 79-87.	3.4	7
16	Simplified platelet sample preparation for <scp>SDS</scp> â€ <scp>PAGE</scp> â€based proteomic studies. Proteomics - Clinical Applications, 2012, 6, 374-381.	1.6	5
17	Staining of proteins for 2D SDSâ€PAGE using Coomassie Blueâ€"speed versus sensitivity?. Electrophoresis, 2013, 34, 1972-1975.	2.4	5
18	Plasma Protein Biomarker Candidates for Myelodysplastic Syndrome Subgroups. BioMed Research International, 2015, 2015, 1-9.	1.9	5

#	Article	IF	CITATIONS
19	Total removal of intact blood plasma proteins deposited on surface-grafted polymer brushes. Analytical Methods, 2016, 8, 6415-6419.	2.7	5
20	Proteome changes of plasma-derived extracellular vesicles in patients with myelodysplastic syndrome. PLoS ONE, 2022, 17, e0262484.	2.5	5
21	Novel homozygous fibrinogen A $\hat{l}\pm$ chain truncation causes severe afibrinogenemia with life threatening complications in a two-year-old boy. Thrombosis Research, 2013, 132, 490-492.	1.7	4
22	N-Glycosylation of apolipoprotein A1 in cardiovascular diseases. Translational Research, 2015, 165, 360-362.	5.0	4
23	Alpha-2-HS-glycoprotein plasma level decrease correlates with age in patients with myelodysplastic syndromes. Cancer Biomarkers, 2017, 20, 637-639.	1.7	4
24	Complement Activation Dramatically Accelerates Blood Plasma Fouling On Antifouling Poly(2â€hydroxyethyl methacrylate) Brush Surfaces. Macromolecular Bioscience, 2022, 22, e2100460.	4.1	4
25	The effect of the biological variability of samples on Coomassie blue dye based fast staining for SDS-PAGE in nonfixed gels. Electrophoresis, 2014, 35, 3008-3011.	2.4	3
26	Peripheral Blood Mononuclear Cell Proteome Changes in Patients with Myelodysplastic Syndrome. BioMed Research International, 2015, 2015, 1-17.	1.9	3
27	Extension of the Human Fibrinogen Database with Detailed Clinical Informationâ€"The αC-Connector Segment. International Journal of Molecular Sciences, 2022, 23, 132.	4.1	3
28	Proteomic analysis of plasma samples from acute coronary syndrome patients — The pilot study. International Journal of Cardiology, 2012, 157, 126-128.	1.7	2
29	Abnormal Fibrinogen ZIÃn (γThr21lle) with Missense Mutation Causing Hypofibrinogenemia. Acta Haematologica, 2014, 132, 140-143.	1.4	2
30	Proteomic analysis of the plasma samples of patients with stable angina pectoris. Cor Et Vasa, 2012, 54, e22-e26.	0.1	1
31	Protein Carbonylation in Patients with Myelodysplastic Syndromes. Blood, 2015, 126, 5232-5232.	1.4	1
32	Posttranslational Modifications of Red Blood Cell Ghost Proteins as "Signatures―for Distinguishing between Low- and High-Risk Myelodysplastic Syndrome Patients. Turkish Journal of Haematology, 2017, 34, 111-113.	0.5	1
33	Mass spectrometry, data re-analysis, and homology modelling predict posttranslational modifications of leucine-rich alpha-2-glycoprotein as a marker of myelodysplastic syndrome. Cancer Biomarkers, 2022, , 1-8.	1.7	0